Moreover, non-diabetic plasma-treated SVFs are capable of mitigating diabetes-induced plasma DPP4 activity, liver inflammation, and insulin resistance, which may be mediated by suppressing M1 cytokines and increasing IL-10 and Tregs in the adipose tissue [31]. The gene discussed is IL10; the disease is diabetes mellitus.